Chester County News and Community Website
MALVERN, PA — Ocugen Inc. (Nasdaq: OCGN) has dosed the first patient in a global Phase 3 trial of OCU410, moving its one-time gene therapy for geographic atrophy into pivotal …
Malvern’s Ocugen Starts Pivotal Trial for Eye Gene Therapy Read More
WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) has completed enrollment in the first pivotal Phase 3 trial of YCANTH for common warts and passed an interim statistical review …
Verrica Advances Wart Drug Expansion as Phase 3 Trial Fills Read More
PHOENIXVILLE, PA — PleoPharma Inc. secured a $6.5 million federal grant to advance a Phase 3 trial of its experimental treatment for cannabis withdrawal symptoms, providing three years of funding …
PleoPharma Wins $6.5 Million NIH Grant for Phase 3 Trial Read More
WASHINGTON, D.C. — The U.S. Department of Veterans Affairs is launching a randomized clinical trial of psilocybin for veterans with treatment-resistant major depressive disorder, including participants with concurrent post-traumatic stress …
VA Launches Psilocybin Trial for Treatment-Resistant Depression Read More
KING OF PRUSSIA, PA — CSL plans to seek approval to expand ANDEMBRY to children ages 2 through 11 after a Phase 3b study found most participants remained free of …
CSL Plans Pediatric ANDEMBRY Filing After Phase 3b Data Read More MALVERN, PA — The U.S. Food and Drug Administration granted Regenerative Medicine Advanced Therapy designation to Ocugen Inc.’s experimental OCU410 gene therapy for geographic atrophy, giving the blindness treatment access …
FDA Gives Ocugen Gene Therapy Expedited Regulatory Status Read More
WASHINGTON, D.C. — The Department of Health and Human Services said the Trump administration has adopted a government-wide policy prohibiting federal funding for what it defines as dangerous gain-of-function research …
HHS Bars Federal Funding for High-Risk Gain-of-Function Research Read More
MALVERN, PA — MAXONA Pharmaceuticals has received U.S. Food and Drug Administration clearance to begin a Phase 2 clinical trial of its investigational non-opioid pain therapy, advancing the company’s effort …
FDA Clears MAXONA Pain Drug for Phase 2 Trial Read More
WEST CHESTER, PA — Molecular Targeting Technologies Inc. (MTTI) will present clinical data from 81 patients at the 5th Targeted Radiopharmaceuticals Summit, offering evidence that its Evans Blue drug delivery …
MTTI to Present 81-Patient Radiopharma Data at Oncology Summit Read More
MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has completed enrollment in its pivotal Phase 3 Alzheimer’s disease trial, positioning the biotechnology company for two planned U.S. regulatory submissions beginning …
Annovis Completes Enrollment for Alzheimer’s Phase 3 Trial Read More